CRISPR Therapeutics (CRSP) Misses Q1 EPS by 37c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q1 EPS of ($1.58), $0.37 worse than the analyst estimate of ($1.21). Revenue for the quarter came in at $860 thousand versus the consensus estimate of $7.1 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• Microsoft plans data center push to triple its computing power - Bloomberg
• JPMorgan Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance